Cellution Biologics Inc. announced the introduction and availability of AmnioPlast 1 (dehydrated monolayered human amnion membrane allograft) and AmnioPlast Double (Dehydrated, Dual-Layer Amnion Membrane Allograft), intended for use as a cover or barrier applied to the ocular surface following repair or reconstruction procedures of ocular disease and/or abnormalities.

According to a company press release, both grafts are processed aseptically to preserve the native architecture of the amnion while eliminating the need for cryopreservation. The result is ready-to-use membranes that provide consistency and handling ease in both clinic and operating-room settings, the company said. 

According to Cellution Biologics, AmnioPlast 1 is a dehydrated monolayered human amnion membrane allograft intended for use as a cover or barrier applied to the ocular surface following repair or reconstruction procedures of ocular disease and/or abnormalities.

AmnioPlast Double is a dehydrated dual-layer amnion membrane allograft that serves as a barrier and provides protective covering to the ocular surface. These products are sterile, minimally manipulated and are meticulously derived from human placental membranes obtained from healthy, consenting donors, the company said in the press release.